Synonym
Indapamide, Noranat, Fludex, Natrilix, Tertensif
IUPAC/Chemical Name
4-chloro-N-(2-methyl-2,3-dihydroindol-1-yl)-3-sulfamoylbenzamide
InChi Key
NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
SMILES Code
O=C(NN1C(C)CC2=C1C=CC=C2)C3=CC=C(Cl)C(S(=O)(N)=O)=C3
Appearance
White to light yellow crystalline powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
365.83
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension. 2015 May;65(5):1041-6. doi: 10.1161/HYPERTENSIONAHA.114.05021. Epub 2015 Mar 2. Review. PubMed PMID: 25733245.
2: DiNicolantonio JJ, Bhutani J, Lavie CJ, O'Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol. 2015 Mar;11(2):203-17. doi: 10.2217/fca.14.83. Review. PubMed PMID: 25760879.
3: Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother. 2012 Jul;13(10):1515-26. doi: 10.1517/14656566.2012.698611. Review. PubMed PMID: 22725706.
4: de Leeuw PW. Combination perindopril/indapamide for the treatment of hypertension: a review. Expert Opin Pharmacother. 2011 Aug;12(11):1827-33. doi: 10.1517/14656566.2011.585638. Epub 2011 Jun 9. Review. PubMed PMID: 21651456.
5: Mourad JJ, Le Jeune S. Evaluation of high dose of perindopril/indapamide fixed combination in reducing blood pressure and improving end-organ protection in hypertensive patients. Curr Med Res Opin. 2009 Sep;25(9):2271-80. doi: 10.1185/03007990903186787. Review. PubMed PMID: 19627177.
6: Waeber B, de la Sierra A, Ruilope LM. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2009;9(5):283-91. doi: 10.2165/10061600-000000000-00000. Review. PubMed PMID: 19791837.
7: Chalmers J, Joshi R, Kengne AP, Ninomiya T, Bi Y, Bompoint S, Billot L, Patel A; ADVANCE Collaborative Group. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens Suppl. 2008 Sep;26(3):S21-7. Review. PubMed PMID: 19363849.
8: Hamano T, Yamamoto T, Miyamori I, Kuriyama M. [Hyponatremia with somnolence due to indapamide]. Rinsho Shinkeigaku. 2008 Jan;48(1):52-5. Review. Japanese. PubMed PMID: 18386633.
9: Cavalieri L, Cremonesi G. Delapril plus indapamide: a review of the combination in the treatment of hypertension. Clin Drug Investig. 2007;27(6):367-80. Review. PubMed PMID: 17506588.
10: Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs. 2006;66(2):257-71. Review. PubMed PMID: 16451099.
11: Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005 Dec;19(6):637-45. Review. PubMed PMID: 16313275.
12: Laurent S. Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage. J Hypertens Suppl. 2003 Jun;21(3):S11-8. Review. PubMed PMID: 12929470.
13: de Leeuw PW; Joint National Committee; World Health Organization - International Society of Hypertension. Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension. J Hypertens Suppl. 2001 Sep;19(3):S41-5. Review. PubMed PMID: 11713850.
14: Indapamide plus perindopril--simpler treatment, better compliance. Cardiovasc J S Afr. 2001 Apr-May;12(2):119. Review. PubMed PMID: 11474694.
15: Matheson AJ, Cheer SM, Goa KL. Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs. 2001;61(8):1211-29. Review. PubMed PMID: 11465878.
16: Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs. 2000;59 Suppl 2:27-38; discussion 39-40. Review. PubMed PMID: 10678595.
17: Donnelly R. Clinical implications of indapamide sustained release 1.5 mg in hypertension. Clin Pharmacokinet. 1999;37 Suppl 1:21-32. Review. PubMed PMID: 10491730.
18: Bataillard A, Schiavi P, Sassard J. Pharmacological properties of indapamide. Rationale for use in hypertension. Clin Pharmacokinet. 1999;37 Suppl 1:7-12. Review. PubMed PMID: 10491728.
19: Donnelly R, Molyneaux LM, Willey KA, Yue DK. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol. 1996 Feb 22;77(6):26B-30B. Review. PubMed PMID: 8848991.
20: Komajda M, Klimczak K, Evans J, Boutin B, Brackman F, Guez D, Grosgogeat Y. [Long-term effects of indapamide in left ventricular hypertrophy in patients with hypertension]. Arch Mal Coeur Vaiss. 1990 Dec;83 Spec No 4:45-50. Review. French. PubMed PMID: 2150474.
